 |
Global Prostate Cancer Therapeutics Market to 2020
The prostate cancer drugs market is expected to nearly double by 2020, due to the introduction of new, more expensive drugs. Prostate Cancer is the most frequently diagnosed cancer in men. In terms of loss of life from any disease, prostate cancer ranks eleventh; and it ranks sixth in terms of cancer–related mortality in men. The prostate cancer market has a huge demand for new and novel drugs that address unmet needs such as improved survival time, less toxicity, increased progression free survival, increased effectiveness, and lower cost. The global market for the prostate cancer therapeutics market is increasing, driven primarily by the growth in the hormone–refractory prostate cancer therapeutics market. Although, the prostate cancer market faces some hindrances such as the high cost of prostate cancer drugs, the market for prostate cancer drugs is likely to rise in the future.
Global Prostate Cancer Drugs Analysis: Zytiga was the leading prostate cancer drugs in 2014 being followed by Xtandi drugs. In prostate cancer drugs market, Leuplin and Zoladex stand at the third and fourth position respectively in 2014, while Lupron stands at the fifth position in the same year. Bayer's cancer drug Xofigo is also increasing its market share. Decapeptyl, Taxotere, Jevtana and Provenge are the other popular prostate cancer drugs in the global market.
Renub Research report titled “Global Prostate Cancer Therapeutics Market to 2020” provides a comprehensive assessment of the fast–evolving, high–growth of Prostate Cancer Therapeutics Market. This 80 page report with 35 Figures and 2 Tables analyses the Prostate Cancer Therapy Drugs Market, driving factors and challenges for prostate cancer market landscape.
The report covers the following:
1. Global Prostate Cancer – Hormonal Therapy Drugs Market
• Luteinizing Hormone–Releasing Hormone (LHRH) Antagonists
1. Zytiga
2. Gonax
• Luteinizing Hormone–Releasing Hormone (LHRH) Analogs
1. Lupron
2. Zoladex
3. Decapeptyl
4. Eligard
5. Vantas
6. Leuplin
• Anti–Androgens
1. Casodex
2. Xtandi or MDV3100
3. Xtandi US or MDV3100
2. Global Prostate Cancer Chemotherapy Drugs Market
1. Taxotere
2. Jevtana
3. Global Prostate Cancer Immunotherapy Drugs Market
1. Provenge
4. Global Prostate Cancer Targeted Therapy Drugs Market
1. Xofigo or Alpharadin
Data Sources
This report is built using data and information sourced from proprietary databases, primary and secondary research and in–house analysis by Renub Research team of industry experts.
Primary sources include industry surveys and telephone interviews with industry experts.
Secondary sources information and data has been collected from various printable and non–printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.
Click here to view the report details:http://www.renub.com/global-prostate-cancer-therapeutics-market-to-2020-487-p.php
For more information:
Contact Us
Rajat Gupta
Sr. Manager
Sales & Marketing Div
Renub Research
Email: info@renub.com
Phone: Phone: +1-678-302-0700 (USA), +91-120-421-9822, +91-120-424-9780 (India)
Web: http://www.renub.com
Follow us:
https://www.facebook.com/RenubResearch/
https://twitter.com/renubresearch
https://www.linkedin.com/company/renub-research
https://plus.google.com/+renubresearch
https://www.youtube.com/c/renubresearch
Контактное лицо: Rajat Gupta
Компания: Renub Research
Добавлен: 00:21, 09.05.2016
Количество просмотров: 714
Страна: США
| МираксБиоФарма объявляет о новом этапе развития, МираксБиоФарма, 22:12, 21.06.2025, Россия185 |
| Москва, 17 июня 2025 г
Фармацевтическая компания «МираксБиоФарма» завершила ребрендинг и представила обновлённый логотип, фирменный стиль и стратегию развития. Новый образ компании подчёркивает её амбиции и уникальный подход: создание лекарственных препаратов, БАД и косметических средств по модели полного цикла. |
| Агентство IQ реализовало digital размещение для компании СДЭК, посвящённую их 25-летию, Рекламное агентство IQ, 22:47, 18.06.2025, Россия200 |
| С декабря 2024 по март 2025 года агентством IQ была размещена digital реклама компании СДЭК, посвящённая их 25-летию. Трансляция роликов велась в ключевых курортах России — Шерегеш Сектор А, Б, Е, Красная Поляна и Газпром Поляна, что обеспечило охват целевой аудитории премиального и спортивного сегмента. |
| BTL-интеграция Capital Group: продвижение ЖК Бадаевский через гольф-клуб Раево от агентства IQ, Рекламное агентство IQ, 13:10, 10.06.2025, Россия109 |
| В марте 2025 года агентство IQ реализовало BTL-интеграцию для Capital Group в гольф-клубе Раево, направленную на продвижение жилого комплекса «Бадаевский». Кампания состояла из комплексных условий партнёрства в рамках мероприятия «Масленица в Раево» с брендированием, а также активным участием в программе праздника для привлечения премиальной аудитории. |
|
|
